Despite potential improvements in recognition and time to diagnosis, clinical guidelines and the availability of an approved targeted treatment for MCT8 deficiency are needed (1). This evidence concerns the gene SLC16A2 and hyperinsulinemic hypoglycemia, familial, 4.